Waugh, Norman, Black, C. (Corrinda), Walker, S., McIntyre, Linda, Cummins, E. (Ewen) and Hillis, G. S.. (2006) The effectiveness and cost-effectiveness of computed tomography screening for coronary artery disease : systematic review. Health Technology Assessment, Vol.10 (No.39). ISSN 1366-5278

Preview	Text WRAP_Waugh_CT heart 1.pdf - Published Version Download (359Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh3_Coversheet_FinalVersion.pdf Download (200Kb) | Preview

Abstract

Coronary heart disease (CHD) is one of the main causes of mortality and morbidity in the UK and other Western countries. The disease can be asymptomatic until the first event, which may be a fatal myocardial infarction (heart attack). Half of all heart attacks occur in people who have had no prior warning of coronary disease, and almost half will die from the first attack. Risk scores based on well-known factors such as age, blood pressure, smoking, cholesterol and diabetes have been used to assess risk, but are imperfect: not all high-risk people develop heart disease, and many low-risk people do. Indeed, depending on which cut-off is used to define high risk, most heart attacks occur in low-risk people, because the number of people at low risk is much greater than the number at high risk. There is therefore a need for a better way of identifying those at risk so that they can treat themselves with lifestyle measures, or receive drug therapy such as statins and antihypertensive drugs as appropriate. Computed tomography (CT) is a form of radiological imaging that can detect calcium deposits in the coronary arteries. This calcification is a marker for CHD, and so CT imaging could be a way of detecting asymptomatic but serious CHD. CT is quick and non-invasive, but does involve a relatively large radiation dose.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Coronary heart disease -- Diagnosis, Tomography -- Cost effectiveness
Journal or Publication Title:	Health Technology Assessment
Publisher:	National Coordinating Centre for Health Technology Assessment
ISSN:	1366-5278
Date:	October 2006
Volume:	Vol.10
Number:	No.39
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
References:	1. Berry E, Kelly S, Hutton J, Harris KM, Roderick P, Boyce JC, et al. A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease. Health Technol Assess 1999;3(18). 2. British Heart Foundation. Coronary heart disease statistics 2004: Chapter 1. Mortality. URL: http://www.heartstats.org/temp/Mortalityspchapter.pdf. Accessed 15 March 2005. 3. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess in press. 4. Tunstall-Pedoe H, Morrison C, Woodward M, Fitzpatrick B, Watt G. Sex differences in myocardial infarction and coronary death in the Scottish MONICA population of Glasgow 1985 to 1991: presentation, diagnosis, treatment and 28-day case fatality of 3991 events in men and 1551 events in women. Circulation 1996;93:1981–92. 5. American Heart Association. Heart disease and stroke statistics update 2003. Dallas, TX: American Heart Association; 2003. 6. Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000;320:671–6. 7. O’Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, et al. American College of Cardiology/American Heart Association expert consensus document on electronbeam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 2000;36:326–40. 8. Scottish Intercollegiate Guideline Network. Coronary revascularisation in the management of stable angina pectoris. SIGN Publication No. 32. URL: http://www.sign.ac.uk/guidelines/fulltext/32/ index.html 9. Pignone M, Fowler-Brown A, Pletcher M, Tice JA. Screening for asymptomatic coronary artery disease: a systematic review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2003. 10. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71. 11. Guerci AD, Arad Y. Potential use of Ca++ scanning to determine the need for and intensity of lipidlowering therapy in asymptomatic adults. Curr Cardiol Rep 2001;3:408–15. 12. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278–86. 13. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. The Regression Growth Evaluation Statin Study (REGRESS). Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995; 91:2528–40. 14. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633–8. 15. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005;96:61–8F. 16. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. The Canadian Coronary Atherosclerosis Intervention Trial. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959–68. 17. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80:S1–29. 18. National Institute for Health and Clinical Excellence. TA094 Cardiovascular disease – statins – guidance. URL: http://www.nice.org.uk/ page.aspx?o=TA094guidance 19. Schoepf UJ, Becker CR, Ohnesorge BM, Yucel EK. CT of coronary artery disease. Radiology 2004; 232:18–37. 20. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32. 21. Berrington DG, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004;363:345–51. 22. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21:1–201. 23. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998;316:1213–20. 24. Ebrahim S, Davey SG, McCabe C, Payne N, Pickin M, Sheldon TA, et al. What role for statins? A review and economic model. Health Technol Assess 1999;3(19). 25. Maryon-Davis A, Press V, Cardiovascular Health Working Group of the Faculty of Public Health. Easing the pressure: a toolkit for developing a local strategy to tackle high blood pressure. London: Faculty of Public Health, National Heart Forum; 2005. 26. National Institute for Clinical Excellence. Hypertension (persistently high blood pressure) in adults. NICE Clinical Guidelines, No. CG 18. London: NICE; 2004. 27. Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2004;CD003186. 28. Ebrahim S, Davey SG. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2000; CD001561. 29. Hillsdon M, Foster C, Thorogood M. Interventions for promoting physical activity. Cochrane Database Syst Rev 2005;CD003180. 30. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev 2001;CD002137. 31. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;CD003177. 32. Kelly S, Frost G, Whittaker V, Summerbell C. Low glycaemic index diets for coronary heart disease. Cochrane Database Syst Rev 2004;CD004467. 33. Goff DC, Gu L, Cantley LK, Sheedy DJ, Cohen SJ. Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial. Am Heart J 2003;146:1045–51. 34. Rasmussen JN, Gislason GH, Abildstrom SZ, Rasmussen S, Gustafsson I, Buch P, et al. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol 2005; 60:150–8. 35. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002. Br J Clin Pharmacol 2005;59:227–32. 36. Bowker TJ, Clayton TC, Ingham J, McLennan NR, Hobson HL, Pyke SD, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996;75:334–42. 37. Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for carrying out or commissioning reviews. CRD Report No. 4. 2nd ed. York: Centre for Reviews and Dissemination. 38. Agatston A, Janowitz WR, Kaplan G, Lee D, Prashad R, Viamonte MJ, et al. Electron beam CT coronary calcium predicts future coronary events. Circulation 1996;94:I-360. 39. Arad Y, Spadaro L, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253–60. 40. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol 2005;46:158–65. 41. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004; 291:210–15. 42. Itani Y, Sone S, Nakayama T, Suzuki T, Watanabe S, Ito K, et al. Coronary artery calcification detected by a mobile helical computed tomography unit and future cardiovascular death: 4-year follow-up of 6120 asymptomatic Japanese. Heart Vessels 2004; 19:161–3. 43. Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003;107:2571–6. 44. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003;228:826–33. 45. Shivalkar B, Ozsarlak O, Boussy T, Salgado R, Parizel P, Vrints C. Multislice cardiac computer tomography is useful in the detection of coronary artery disease in patients with intermediate Framingham risk score. Eur Heart J 2004; 25(Suppl 1):471. 46. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol 2000;86:495–8. 47. Grundy SM. The changing face of cardiovascular risk. J Am Coll Cardiol 2005;46:173–5. 48. Raggi P. The use of electron-beam computed tomography as a tool for primary prevention. Am J Cardiol 2001;88:28–32J. 49. Becker CR, Majeed A, Crispin A, Knez A, Schoepf UJ, Boekstegers P, et al. CT measurement of coronary calcium mass: impact on global cardiac risk assessment. Eur Radiol 2005;15:96–101. 50. Hoff JA, Daviglus ML, Chomka EV, Krainik AJ, Sevrukov A, Kondos GT. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30,908 healthy individuals. Ann Epidemiol 2003; 13:163–9. 51. O’Malley PG, Rupard EJ, Jones DL, Feuerstein I, Brazaitis M, Taylor AJ. Does the diagnosis of coronary calcification with electron beam computed tomography motivate behavioral change in smokers? Mil Med 2002;167:211–14. 52. O’Malley PG, Feuerstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. JAMA 2003;289:2215–23. 53. Wong ND, Detrano RC, Diamond G, Rezayat C, Mahmoudi R, Chong EC, et al. Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? Am J Cardiol 1996;78:1220–3. 54. O’Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electronbeam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000;85:945–8. 55. Pletcher M, O’Malley PG. Review finds coronary artery calcium score is an independent predictor of coronary events. Evidence Based Cardiovascular Medicine 2004;8:371–3. 56. Institute for Clinical Systems Improvement. Electron-beam and helical computed tomography for coronary artery disease. No. TA 034. Bloomington, MN: ICSI; 2004. 57. Canadian Coordinating Office for Health Technology Assessment. Multislice/spiral computed tomography for screening for coronary artery disease. No. 4. Ottawa: CCOHTA; 2003. 58. Raggi P, Davidson M, Callister TQ, Welty FK, Bachmann GA, Hecht H, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 2005;112:563–71. 59. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005;46:166–72. 60. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Forster A, Friedrich G, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006;113:427–37. 61. Sekikawa A, Ueshima H, Zaky WR, Kadowaki T, Edmundowicz D, Okamura T, et al. Much lower prevalence of coronary calcium detected by electron-beam computed tomography among men aged 40–49 in Japan than in the US, despite a less favorable profile of major risk factors. Int J Epidemiol 2005;34:173–9. 62. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 2005;234:35–43. 63. Liu JLY. The economic burden of coronary heart disease in the UK. Heart 2002;88:597–603. 64. Gray AM, Bowman GS, Thompson DR. The cost of cardiac rehabilitation services in England and Wales. J R Coll Physicians Lond 1997;31:57–61. 65. Stanford W. Screening of coronary artery disease: is there a cost-effective way to do it? American Journal of Cardiac Imaging 1996;10:180–6. 66. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomography, and coronary angiography for diagnosis of coronary artery disease. Circulation 1995;91:54–65. 67. Marwick TH. Cost-effectiveness of stress echocardiography for assessment of coronary artery disease: what we know and what we need to know. Eur J Echocardiogr 2000;1:22–31. 68. O’Malley PG, Greenberg BA, Taylor AJ. Costeffectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease. Am Heart J 2004; 148:106–13. 69. Shaw LJ, Raggi P, Berman DS, Callister TQ. Cost effectiveness of screening for cardiovascular disease with measures of coronary calcium. Prog Cardiovasc Dis 2003;46:171–84. 70. Shaw LJ, Callister TQ, Raggi P. Establishing cost effective thresholds for coronary disease screening: a predictive model with risk factors and coronary calcium. Circulation 2001;104:478–9. 71. Rumberger JA. Cost effectiveness of coronary calcification scanning using electron beam tomography in intermediate and high risk asymptomatic individuals. J Cardiovasc Risk 2000; 7:113–19. 72. Wonderling D, McDermott C, Buxton M, Kinmonth A-L, Pyke S, Thompson S, et al. Costs and cost effectiveness of cardiovascular screening and intervention: the British Family Heart Study. BMJ 1996;312:1269–73. 73. Shepherd J. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. Am J Cardiol 2001; 87:19–22B. 74. Ramachandran S, French JM, Vanderpump MP, Croft P, Neary RH. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ 2000;320:676–7. 75. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004;291:71–8. 76. Chan ECY. Promoting an ethical approach to unproven screening imaging tests. J Am Coll Radiol 2005;2:311–20. 77. Picano E. Informed consent and communication of risk from radiological and nuclear medicine examinations: how to escape from a communication inferno. BMJ 2004;329:849–51. 78. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. URL: http://www.nsc.nhs.uk/pdfs/criteria.pdf 79. Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. Health Technol Assess 2005; 9(17). 80. Horton KM, Post WS, Blumenthal RS, Fishman EK. Prevalence of significant noncardiac findings on electron-beam computed tomography coronary artery calcium screening examinations. Circulation 2002;106:532–4. 81. van Ooijen PM, Vliegenthart R, Witteman JC, Oudkerk M. Influence of scoring parameter settings on Agatston and volume scores for coronary calcification. Eur Radiol 2005;15:102–10. 82. Anand DV, Lim E, Raval U, Lipkin D, Lahiri A. Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography. J Nucl Cardiol 2004;11:450–7. 83. Takamiya T, Zaky WR, Edmundowics D, Kadowaki T, Ueshima H, Kuller LH, et al. World Health Organization-defined metabolic syndrome is a better predictor of coronary calcium than the adult treatment panel III criteria in American men aged 40–49 years. Diabetes Care 2004;27:2977–9. 84. Sullivan CJ, Fisher BT, Bagai J, Chomka EV, Devries SR, Hoff JA, et al. Coronary artery calcium screening by electron beam computed tomography: a four year follow-up for coronary events. Circulation 1998;98(Suppl S):656. 85. Raggi P, Callister TQ, Cooil B, He ZX, Lippolis NJ, Russo DJ, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000;101:850–5. 86. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J 2001;141:375–82. 87. Yang T, Doherty TM, Wong ND, Detrano RC. Alcohol consumption, coronary calcium, and coronary heart disease events. Am J Cardiol 1999; 84:802–6.
URI:	http://wrap.warwick.ac.uk/id/eprint/50150

Request changes to a record

Actions (login required)

View Item